Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm

Area of Science:

• Microbiology
• Immunology
• Vaccine Development

Background:

• Group B Streptococcus (GBS), or Streptococcus agalactiae, is a significant human pathogen.
• Three distinct pilus variants, each encoded by a unique pathogenicity island, have been identified in GBS.
• Previous studies demonstrated that GBS pilus components can induce protective immunity in mice.

Purpose of the Study:

• To evaluate the potential of a combined pilus-based vaccine for broad protection against GBS.
• To assess the distribution and conservation of pilus variants across clinical GBS isolates.

Main Methods:

• Analysis of pili distribution and sequence conservation in 289 clinical isolates of Streptococcus agalactiae.
• Testing the protective efficacy of a vaccine composed of proteins from the three pilus types against homologous GBS challenge in a mouse model.

Main Results:

• Pilus sequences within each pathogenicity island were found to be highly conserved.
• Every analyzed GBS strain harbored at least one of the three identified pilus islands.
• A combination vaccine containing all three pilus components demonstrated protective efficacy against all tested GBS challenge strains.

Conclusions:

• A vaccine solely composed of GBS pilus components can effectively prevent GBS infections.
• This pilus-based vaccination strategy holds potential for preventing infections caused by Streptococcus agalactiae.
• The findings suggest a similar vaccine approach may be applicable to other pathogenic streptococci.